A 1,650-patient study was launched by Medtronic to evaluate the effect of using capnography and pulse oximetry in opioid-induced respiratory depression. The study will use 48-hour continuous pulse oximetry and capnography monitoring with the company's Capnostream device to develop an OIRD risk assessment scoring tool for use in patients receiving opioids for pain.
Study launched by Medtronic to create OIRD risk assessment scoring tool
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.